Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger
Issued Date
2023-09-06
Resource Type
eISSN
14761645
Scopus ID
2-s2.0-85170111608
Pubmed ID
37580026
Journal Title
The American journal of tropical medicine and hygiene
Volume
109
Issue
3
Start Page
511
End Page
514
Rights Holder(s)
SCOPUS
Bibliographic Citation
The American journal of tropical medicine and hygiene Vol.109 No.3 (2023) , 511-514
Suggested Citation
Kabore Y., Vatrinet R., Guindo O., Moussa S.H., Schilling W.H.K., Grais R.F. Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger. The American journal of tropical medicine and hygiene Vol.109 No.3 (2023) , 511-514. 514. doi:10.4269/ajtmh.22-0606 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/90021
Title
Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger
Other Contributor(s)
Abstract
In 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a rapidly emerging virus causing the coronavirus disease 2019 (COVID-19) pandemic, had no known effective prophylaxis and no widely available proven effective antiviral treatment. Hydroxychloroquine/Chloroquine was identified as an early potential therapeutic candidate drawing on evidence from reports of both in vitro and in vivo testing. A multicountry placebo-controlled randomized trial was set to evaluate the use of hydroxychloroquine/chloroquine to prevent infection in healthcare workers and staff working in a health facility involved in COVID-19 management. One of the sites of this trial was in Niger. In Niger, of the 240 persons who were provided information about the study and with whom participation was discussed, only five participants provided their informed consent. In this article, we describe the key difficulties encountered in the conduct of this trial from the perspective of the site study team. Among the difficulties, we recognize that the epidemic context, controversy surrounding hydroxychloroquine, vaccine rollout, participants' perspectives, and trial design had a major impact on participation.